Identification

Name
Oxymetazoline
Accession Number
DB00935  (APRD01158)
Type
Small Molecule
Groups
Approved, Investigational
Description

A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)

Structure
Thumb
Synonyms
  • 2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
  • 3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
  • 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
  • 6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
  • Oximetazolinum
  • Oxymetazolina
  • Oxymetazolinum
  • Oxymethazoline
  • Oxymetozoline
Product Ingredients
IngredientUNIICASInChI Key
Oxymetazoline hydrochlorideK89MJ0S5VY2315-02-8BEEDODBODQVSIM-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clirol Nasal SpraySpray0.5 %NasalComplex Pharma Inc.Not applicableNot applicableCanada
RhofadeCream10 mg/gTopicalAllergan2017-01-18Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
12 Hour NasalSpray.05 g/100mLNasalSelect Brands Distributors2000-03-01Not applicableUs
12 Hour NasalSpray.05 g/100mLNasalMeijer Distribution2015-05-06Not applicableUs
12 Hour NasalSpray.05 g/100mLNasalHealthlife of Usa2018-01-02Not applicableUs
12 Hour NasalSpray.05 g/100mLNasalAltaire Pharmaceuticals Inc.2001-06-01Not applicableUs
12 Hour Original Nasal DecongestantLiquid50 mg/100mLNasalFaria Llc Dba Sheffield Pharmaceutcials2014-05-30Not applicableUs
12 Hour Original Nasal DecongestantLiquid50 mg/100mLNasalPreferreed Pharmaceuticals Inc.2018-01-02Not applicableUs
7 Select NasalSpray.05 g/100mLNasal7 Eleven2014-08-05Not applicableUs
7 Select Original NasalSpray.05 g/mLNasal7 Eleven2016-10-04Not applicableUs
AfrinSpray.5 mg/mLTopicalNavajo Manuracturing Company2017-12-04Not applicableUs
Afrin ColdSpray0.05 mgNasalSchering Plough2002-09-282006-08-01Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
KovanazeOxymetazoline hydrochloride (.5 mg/mL) + Tetracaine hydrochloride (30 mg/mL)SprayNasalSt. Renatus2016-09-01Not applicableUs
International/Other Brands
Afrin / Dristan 12-Hour / Duramist Plus / Genasal Nasal Spray Up to 12 Hour Relief / Iliadin / Neo-Synephrine 12 Hour Spray / Nezeril / Nostrilla 12 Hour Nasal Decongestant / OcuClear / Vicks Sinex 12 Hour Nasal Spray / Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief
Categories
UNII
8VLN5B44ZY
CAS number
1491-59-4
Weight
Average: 260.3746
Monoisotopic: 260.1888634
Chemical Formula
C16H24N2O
InChI Key
WYWIFABBXFUGLM-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)
IUPAC Name
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
SMILES
CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C

Pharmacology

Indication

For treatment of nasal congestion and redness associated with minor irritations of the eye

Associated Conditions
Pharmacodynamics

Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.

Mechanism of action

Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
partial agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
binder
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3-isobutyl-1-methyl-7H-xanthine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 6-O-benzylguanine.Investigational
7-DeazaguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7-Deazaguanine.Experimental
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7,9-Dimethylguanine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-azaguanine.Experimental
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-chlorotheophylline.Approved
9-DeazaguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Deazaguanine.Experimental
9-MethylguanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Methylguanine.Experimental
AcebutololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acebutolol.Approved, Investigational
AcefyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acefylline.Experimental
AcepromazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AcyclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acyclovir.Approved
Ajulemic acidThe risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Oxymetazoline.Investigational
AlfuzosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlprenololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alprenolol.Approved, Withdrawn
AmineptineAmineptine may increase the vasopressor activities of Oxymetazoline.Illicit, Withdrawn
AmitriptylineAmitriptyline may increase the vasopressor activities of Oxymetazoline.Approved
AmitriptylinoxideAmitriptylinoxide may increase the vasopressor activities of Oxymetazoline.Approved, Investigational
AmoxapineAmoxapine may increase the vasopressor activities of Oxymetazoline.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Oxymetazoline.Approved, Illicit, Investigational
AnisodamineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Anisodamine.Investigational
AripiprazoleThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Arotinolol.Investigational
AsenapineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Asenapine.Approved
AtenololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Atenolol.Approved
AtomoxetineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Oxymetazoline.Approved
AzathioprineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Azathioprine.Approved
BamifyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bamifylline.Experimental
BefunololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Befunolol.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Oxymetazoline.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.Approved, Illicit
Benzylpenicilloyl PolylysineOxymetazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetaxololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bevantolol.Approved
BisoprololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bisoprolol.Approved
BopindololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bopindolol.Approved
BrexpiprazoleThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
BromotheophyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bromotheophylline.Approved
BucindololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bucindolol.Investigational
BufuralolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bufuralol.Experimental, Investigational
BufyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bufylline.Experimental
BunazosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bunazosin.Investigational
BupranololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bupranolol.Approved
ButriptylineButriptyline may increase the vasopressor activities of Oxymetazoline.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
CafedrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Caffeine.Approved
CannabidiolThe risk or severity of Tachycardia can be increased when Cannabidiol is combined with Oxymetazoline.Approved, Investigational
CaroxazoneCaroxazone may increase the hypertensive activities of Oxymetazoline.Withdrawn
CarteololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Carteolol.Approved
CarvedilolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Celiprolol.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the vasopressor activities of Oxymetazoline.Approved, Investigational, Vet Approved
CloranololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Cloranolol.Experimental
ClozapineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Clozapine.Approved
CP-945598The risk or severity of Tachycardia can be increased when CP-945598 is combined with Oxymetazoline.Investigational
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Oxymetazoline.Approved
DapiprazoleThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dapiprazole.Approved
DesipramineDesipramine may increase the vasopressor activities of Oxymetazoline.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Oxymetazoline.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dextroamphetamine.Approved, Illicit
DibenzepinDibenzepin may increase the vasopressor activities of Oxymetazoline.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Diethylpropion.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
DimetacrineDimetacrine may increase the vasopressor activities of Oxymetazoline.Approved, Withdrawn
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Oxymetazoline.Approved
DopamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dopamine.Approved
DosulepinDosulepin may increase the vasopressor activities of Oxymetazoline.Approved
DoxazosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Doxazosin.Approved
DoxepinDoxepin may increase the vasopressor activities of Oxymetazoline.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Doxofylline.Approved, Investigational
DronabinolThe risk or severity of Tachycardia can be increased when Dronabinol is combined with Oxymetazoline.Approved, Illicit
DronedaroneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Oxymetazoline.Approved
EntecavirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Entecavir.Approved, Investigational
EpanololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Oxymetazoline.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
EsatenololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esatenolol.Experimental
EsmololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esmolol.Approved
EtamiphyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etamiphylline.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etilefrine.Withdrawn
FenethyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenethylline.Approved
FenoterolThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenozolone.Experimental
FentanylThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Oxymetazoline.Approved, Illicit, Investigational, Vet Approved
FlupentixolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FurafyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Furafylline.Experimental
FurazolidoneFurazolidone may increase the hypertensive activities of Oxymetazoline.Approved, Investigational, Vet Approved
GanciclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ganciclovir.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Gepefrine.Experimental
GuanineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Guanine.Experimental
GW842166The risk or severity of Tachycardia can be increased when GW842166 is combined with Oxymetazoline.Investigational
HarmalineHarmaline may increase the hypertensive activities of Oxymetazoline.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Oxymetazoline.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Oxymetazoline.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hydroxyamphetamine.Approved
HypoxanthineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hypoxanthine.Experimental
IbipinabantThe risk or severity of Tachycardia can be increased when Ibipinabant is combined with Oxymetazoline.Investigational
IloperidoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Iloperidone.Approved
ImipramineImipramine may increase the vasopressor activities of Oxymetazoline.Approved
Imipramine oxideImipramine oxide may increase the vasopressor activities of Oxymetazoline.Experimental
IndenololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indenolol.Withdrawn
IndoraminThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indoramin.Withdrawn
IobenguaneOxymetazoline can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Iofetamine I-123.Approved
IprindoleIprindole may increase the vasopressor activities of Oxymetazoline.Experimental
IproniazidIproniazid may increase the hypertensive activities of Oxymetazoline.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Oxymetazoline.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Labetalol.Approved
LandiololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Landiolol.Investigational
LevobetaxololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Levobunolol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Oxymetazoline.Approved, Investigational
LinezolidThe risk or severity of hypertension can be increased when Linezolid is combined with Oxymetazoline.Approved, Investigational
LisdexamfetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisdexamfetamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisofylline.Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
LobucavirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lobucavir.Investigational
LofepramineLofepramine may increase the vasopressor activities of Oxymetazoline.Experimental
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Illicit, Investigational, Withdrawn
MebanazineMebanazine may increase the hypertensive activities of Oxymetazoline.Withdrawn
MefenorexThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mefenorex.Experimental
MelitracenMelitracen may increase the vasopressor activities of Oxymetazoline.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephedrone.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.Approved
MepindololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mepindolol.Experimental
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Oxymetazoline.Approved, Investigational
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methamphetamine.Approved, Illicit
MethotrimeprazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Oxymetazoline.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methoxyphenamine.Experimental
Methylene blueMethylene blue may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved
MetipranololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metipranolol.Approved
MetoprololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mianserin.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Oxymetazoline.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Midomafetamine.Experimental, Illicit, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Oxymetazoline.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Oxymetazoline.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Oxymetazoline.Approved
MMDAThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
NabiloneThe risk or severity of Tachycardia can be increased when Nabilone is combined with Oxymetazoline.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia can be increased when Nabiximols is combined with Oxymetazoline.Approved, Investigational
NadololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nadolol.Approved
NebivololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Oxymetazoline.Withdrawn
NicardipineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
NiguldipineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Niguldipine.Experimental
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Oxymetazoline.Approved
NortriptylineNortriptyline may increase the vasopressor activities of Oxymetazoline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Oxymetazoline.Withdrawn
OlanzapineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Olanzapine.Approved, Investigational
OpipramolOpipramol may increase the vasopressor activities of Oxymetazoline.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Oxymetazoline.Approved
OxaprotilineOxaprotiline may increase the vasopressor activities of Oxymetazoline.Experimental
OxprenololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Oxprenolol.Approved
OxtriphyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Oxtriphylline.Approved
PaliperidoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Paliperidone.Approved
PalmidrolThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Oxymetazoline.Experimental, Nutraceutical
PargylinePargyline may increase the hypertensive activities of Oxymetazoline.Approved
Patent BlueThe risk or severity of hypotension can be increased when Patent Blue is combined with Oxymetazoline.Approved
PeldesineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Peldesine.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pemetrexed.Approved, Investigational
PenbutololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Penbutolol.Approved, Investigational
PenciclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Penciclovir.Approved
PentifyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentifylline.Experimental
PentoxifyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentoxifylline.Approved, Investigational
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational, Vet Approved, Withdrawn
PhenelzinePhenelzine may increase the hypertensive activities of Oxymetazoline.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Oxymetazoline.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Oxymetazoline.Approved, Illicit
PhenoxybenzamineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Oxymetazoline.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Oxymetazoline.Approved, Illicit
PhentolamineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phentolamine.Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Oxymetazoline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Oxymetazoline.Approved, Vet Approved, Withdrawn
PindololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pindolol.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Oxymetazoline.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Oxymetazoline.Withdrawn
PizotifenThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pizotifen.Approved
PractololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Practolol.Approved
PrazosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Procaterol.Approved, Investigational
PromazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Promazine.Approved, Vet Approved
PropafenoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propafenone.Approved
PropentofyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propentofylline.Investigational
PropericiazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiverine.Approved, Investigational
PropranololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Oxymetazoline.Approved
ProxyphyllineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Proxyphylline.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pseudoephedrine.Approved
QuetiapineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quetiapine.Approved
QuinidineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quinidine.Approved, Investigational
QuinupramineQuinupramine may increase the vasopressor activities of Oxymetazoline.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Racepinephrine.Approved
RasagilineRasagiline may increase the hypertensive activities of Oxymetazoline.Approved
RimonabantThe risk or severity of Tachycardia can be increased when Rimonabant is combined with Oxymetazoline.Approved, Investigational
RisperidoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Risperidone.Approved, Investigational
RitobegronThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline.Approved, Investigational
SafinamideSafinamide may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Oxymetazoline.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Oxymetazoline.Approved, Investigational, Vet Approved
SibutramineSibutramine may increase the tachycardic activities of Oxymetazoline.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Silodosin.Approved
SLV319The risk or severity of Tachycardia can be increased when SLV319 is combined with Oxymetazoline.Investigational
SotalolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Sotalol.Approved
SpironolactoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Spironolactone.Approved
SurinabantThe risk or severity of Tachycardia can be increased when Surinabant is combined with Oxymetazoline.Investigational
SynephrineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Synephrine.Experimental
TalinololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Talinolol.Investigational
TamsulosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tamsulosin.Approved, Investigational
Tedizolid phosphateTedizolid phosphate may increase the hypertensive activities of Oxymetazoline.Approved
TerazosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline.Approved
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Experimental
TertatololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tertatolol.Experimental
TetryzolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tetryzoline.Approved
TheobromineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theobromine.Approved, Investigational
TheodrenalineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theodrenaline.Investigational
ThioproperazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioridazine.Approved, Withdrawn
TianeptineTianeptine may increase the vasopressor activities of Oxymetazoline.Approved, Investigational
TimololThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Timolol.Approved
TolazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tolazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypertensive activities of Oxymetazoline.Approved
TramazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tramazoline.Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
TrazodoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trazodone.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tretoquinol.Experimental
TrifluoperazineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrimazosinThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trimazosin.Experimental
TrimipramineTrimipramine may increase the vasopressor activities of Oxymetazoline.Approved
TyramineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tyramine.Investigational, Nutraceutical
UrapidilThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Urapidil.Investigational
Uric AcidThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Uric Acid.Experimental, Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valaciclovir.Approved, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valganciclovir.Approved, Investigational
ValomaciclovirThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valomaciclovir.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Oxymetazoline.Approved
VerapamilThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Verapamil.Approved
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Oxymetazoline.Experimental
XanthineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Xanthine.Experimental
ZiprasidoneThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Ziprasidone.Approved
ZuclopenthixolThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015070
KEGG Compound
C07363
PubChem Compound
4636
PubChem Substance
46505622
ChemSpider
4475
BindingDB
30712
ChEBI
7862
ChEMBL
CHEMBL762
Therapeutic Targets Database
DAP000235
PharmGKB
PA164748840
IUPHAR
124
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxymetazoline
ATC Codes
R01AA05 — OxymetazolineR01AB07 — OxymetazolineS01GA04 — Oxymetazoline
AHFS Codes
  • 52:32.00 — Vasoconstrictors
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic ScienceAnaesthesia therapy1
1CompletedBasic ScienceAcute Rhinitis1
1CompletedTreatmentAllergic Rhinitis (AR)2
1CompletedTreatmentAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine / Healthy Volunteers1
1Not Yet RecruitingTreatmentIncontinence, Fecal1
1, 2CompletedTreatmentIncontinence, Fecal / Spinal Cord Injuries (SCI)1
2CompletedPreventionConjunctivitis, Seasonal Allergic1
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAnaesthesia therapy3
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2WithdrawnTreatmentAnesthesia, Dental / Intranasal Drug Administration / Nasal Surgical Procedures1
3CompletedTreatmentAnaesthesia therapy3
3CompletedTreatmentErythemas / Rosaceas2
3CompletedTreatmentHerpes Simplex Labialis1
3RecruitingTreatmentNasal Stuffiness / Rhinitis1
3RecruitingTreatmentRosaceas1
3TerminatedTreatmentAnaesthesia therapy1
4CompletedTreatmentAdenoidal Hypertrophy1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentNasal Obstruction Present Finding1
4CompletedTreatmentRosaceas1
4Not Yet RecruitingOtherLocal Anesthetic Drug Adverse Reaction / Local Infiltration / Pulp Disease, Dental1
4Not Yet RecruitingTreatmentChronic Nasal Congestion / Sleep Apnea Syndrome1
4RecruitingPreventionThroat Disorder1
4WithdrawnTreatmentAllergic Rhinitis (AR) / Rhinitis Medicamentosa / Tachyphylaxis1
Not AvailableCompletedTreatmentAdenoidectomy / Functional Endoscopic Sinus Surgery (FESS) / Turbinate Surgery1
Not AvailableCompletedTreatmentBlood Pressures / Nasal Bleeding1
Not AvailableCompletedTreatmentNasal Obstruction1
Not AvailableRecruitingBasic ScienceMiddle Ear Disease / Nasal Allergies1
Not AvailableTerminatedTreatmentChronic Rhinitis1

Pharmacoeconomics

Manufacturers
  • Schering plough healthcare products inc
  • Johnson and johnson group consumer companies
Packagers
  • Altaire Pharmaceuticals
  • Bayer Healthcare
  • Chain Drug
  • CVS Pharmacy
  • Palmetto Pharmaceuticals Inc.
  • Perrigo Co.
  • Pfizer Inc.
  • S&P Healthcare
  • Spectrum Pharmaceuticals
  • Target Corp.
  • Walgreen Co.
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
LiquidNasal50 mg/100mL
SprayNasal.05 g/mL
SprayTopical.5 mg/mL
SprayNasal0.05 mg
Spray, meteredNasal.05 g/100mL
Spray, meteredNasal.05 mg/mL
SprayNasal.05 g/100mL
SprayNasal.2 mg/.4mL
SprayNasal0.5 %
SprayNasal.0005 g/mL
SprayNasal.5 mg/mL
SprayNasal
SprayNasal.05 mg/100mg
LiquidNasal0.05 %
SprayNasal0.05 %
SolutionNasal.5 mg/mL
SolutionNasal.05 g/100mL
SolutionNasal.05 mg/100mL
Solution / drops; sprayNasal.025 %
SprayNasal5 g/100mL
SprayNasal.05 mg/mL
LiquidTopical.05 g/100mL
Spray, meteredNasal.0005 mL/100mL
Spray, meteredNasal.05 mg/100mL
Solution / dropsOphthalmic.25 mg
Spray, meteredNasal0.05 %
SprayOral.5 mg/mL
Spray, meteredNasal.2 mg/.4mL
Spray, meteredNasal.5 mg/mL
CreamTopical10 mg/g
SprayNasal7.5 mg/15mL
SprayNasal50 mg/100mL
SprayNasal.05 mg/100mL
SprayNasal.512 mg/mL
SprayNasal.0005055 g/mL
SprayNasal.000512 g/mL
SprayNasal.0005095 g/mL
LiquidNasal.05 %
LiquidOphthalmic.25 mg/mL
LiquidOphthalmic.025 %
Solution / dropsOphthalmic0.025 %
SprayNasal.005 g/100mL
SolutionNasal0.05 %
Prices
Unit descriptionCostUnit
Oxymetazoline hcl powder84.42USD g
Afrin 0.05% nose spray0.62USD ml
Drixoral cold & allergy tablet sa0.4USD tablet
Afrin no drip sinus pump mist0.38USD ml
Oxymetazoline 0.05% spray0.38USD ml
Anefrin 0.05% nasal spray0.37USD ml
Afrin sinus spray0.33USD ml
Dristan long lasting mist0.32USD ml
Neo-synephrine 12 hour spray0.28USD ml
Visine long lasting eye drops0.27USD ml
12 hour nasal relief spray0.24USD ml
Dristan cold multi-symp tablet0.23USD tablet
Ocuclear eye drops0.23USD ml
CVS Pharmacy nasal spray 0.05%0.22USD ml
No drip 0.05% nasal spray0.13USD ml
Nasal spray 0.05%0.06USD ml
Sinus nasal spray0.06USD ml
Nasal decongestant 0.05% spray0.03USD ml
Pv nasal spray 0.05%0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8580282No2010-04-022030-04-02Us
US6413499No2000-03-202020-03-20Us
US9308191No2010-04-022030-04-02Us
US8883838No2011-12-012031-12-01Us
US7812049No2008-05-022028-05-02Us
US8420688No2004-08-022024-08-02Us
US9974773No2015-06-112035-06-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182 °CPhysProp
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0515 mg/mLALOGPS
logP3.7ALOGPS
logP3.03ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)10.91ChemAxon
pKa (Strongest Basic)10.15ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area44.62 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity79.8 m3·mol-1ChemAxon
Polarizability30.64 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9761
Blood Brain Barrier-0.5388
Caco-2 permeable-0.567
P-glycoprotein substrateSubstrate0.8858
P-glycoprotein inhibitor INon-inhibitor0.9477
P-glycoprotein inhibitor IINon-inhibitor0.6585
Renal organic cation transporterInhibitor0.6039
CYP450 2C9 substrateNon-substrate0.7585
CYP450 2D6 substrateNon-substrate0.5707
CYP450 3A4 substrateNon-substrate0.5394
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.854
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.7951
CarcinogenicityNon-carcinogens0.8923
BiodegradationNot ready biodegradable1.0
Rat acute toxicity4.4155 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8402
hERG inhibition (predictor II)Non-inhibitor0.7432
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as xylenols. These are aromatic compounds that contain a xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups, and at least one hydroxyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Xylenes
Direct Parent
Xylenols
Alternative Parents
Phenylpropanes / m-Xylenes / Para cresols / Ortho cresols / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds
show 3 more
Substituents
Xylenol / Phenylpropane / M-xylene / O-cresol / P-cresol / Phenol / Imidolactam / 2-imidazoline / Amidine / Carboxylic acid amidine
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
phenols, carboxamidine, imidazolines (CHEBI:7862)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610]
  2. Deplanne V, Galzin AM: Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther. 1996 Aug;278(2):527-34. [PubMed:8768700]
  3. Shibata K, Taketani K: [Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons]. Fukuoka Igaku Zasshi. 2001 Nov;92(11):377-83. [PubMed:11774707]
  4. Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol. 1995 Sep;116(1):1605-10. [PubMed:8564226]
  5. Gonzalez-Espinosa C, Romero-Avila MT, Mora-Rodriguez DM, Gonzalez-Espinosa D, Garcia-Sainz JA: Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor. Eur J Pharmacol. 2001 Aug 31;426(3):147-55. [PubMed:11527538]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
Partial agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM: [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011-8. [PubMed:1327384]
  2. Mitrani P, Srinivasan M, Dodds C, Patel MS: Role of the autonomic nervous system in the development of hyperinsulinemia by high-carbohydrate formula feeding to neonatal rats. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1069-78. Epub 2006 Dec 12. [PubMed:17164433]
  3. Lepretre N, Mironneau J: Alpha 2-adrenoceptors activate dihydropyridine-sensitive calcium channels via Gi-proteins and protein kinase C in rat portal vein myocytes. Pflugers Arch. 1994 Dec;429(2):253-61. [PubMed:7892112]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]
  2. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
  2. Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
  3. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
  2. Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
  3. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:46